Gilead Sciences Inc.

Mrs. Hills joined Gilead's Board of Directors in 2007. She is currently the Chair and Chief Executive Officer of Hills & Company, a firm providing advice to U.S. businesses on investment, trade and risk assessment issues outside the United States. Mrs. Hills serves on the international advisory boards of J.P. Morgan Chase, American International Group, Rolls Royce and the Coca-Cola Company. She is Chair of the Inter-American Dialogue and the National Committee on U.S.-China Relations, Co-Chair of the Council on Foreign Relations and the International Advisory Board of the Center for Strategic and International Studies, a member of the Executive Committee of the Peterson Institute for International Economics and the Trilateral Commission and a member of the board of the U.S.-China Business Council and the International Crisis Group. Mrs. Hills served as U.S. Trade Representative from 1989 to 1993 and was principal advisor on international trade to President George H. W. Bush. Under President Gerald Ford, Mrs. Hills served as Secretary of Housing and Urban Development.

Dr. Martin joined Gilead Sciences in 1990 and currently serves as Chairman of the Board of Directors and Chief Executive Officer. He served as President and Chief Executive Officer from 1996 through May 2008. Prior to joining Gilead, Dr. Martin held several leadership positions in the antiviral chemistry division at Bristol-Myers Squibb and served for six years with Syntex Corporation, from 1978 until 1984. Dr. Martin is a member of the Presidential Advisory Council on HIV/AIDS and the Board of Directors of Gen-Probe Incorporated. He has been a member of the Board of Directors of the California Healthcare Institute since 2003, and currently serves as Chairman of the Board, a position he also held from 2005-2006. He served as President of the International Society for Antiviral Research from 1998-2000. In 2008, Dr. Martin was inducted into the National Academy of Engineering of the National Academies. Dr. Martin holds a PhD in organic chemistry from the University of Chicago and an MBA in marketing from Golden Gate University. He has received the Isbell Award from the American Chemical Society and the Gertrude B. Elion Award for Scientific Excellence from the International Society for Antiviral Research.

Dr. Louis Lange is a founder of CV Therapeutics and has served as the Chairman of the Board and Chief Executive Officer since August 1992. From 1980 to 1992, Dr. Lange served on the faculty of the Washington University School of Medicine, including a position as Chief of Cardiology at the Jewish Hospital in St. Louis, Missouri, from 1985 to 1992, and as a full Professor of Medicine from 1990 until 1992. Dr. Lange is internationally recognized as an expert in the field of molecular mechanisms of cardiovascular disease. He is currently on the Board of Trustees at the University of Rochester. He also serves on the Executive Committee of the Biotechnology Industry Organization (BIO), as well as the BIO Board of Directors, and he is chair of the Emerging Companies Governing Section. Dr. Lange holds an MD from Harvard Medical School and a PhD in biochemistry from Harvard University.

Norbert W. Bischofberger, age 53, is our Executive Vice President, Research and Development and Chief Scientific Officer. Dr. Bischofberger joined us in 1990 as Director of Organic Chemistry, became Vice President of Organic Chemistry in February 1993 and was named Vice President of Research in August 1995. Dr. Bischofberger was appointed Senior Vice President, Research in January 1998. Dr. Bischofberger was named Senior Vice President, Research and Development in January 2000. He was promoted to Executive Vice President, Research and Development in November 2000 and to Chief Scientific Officer in March 2007. Prior to joining us, Dr. Bischofberger was a senior scientist in Genentech, Inc. s DNA Synthesis group from 1986 to 1990. He received his B.S. in Chemistry at the University of Innsbruck in Austria and his Ph.D. in Organic Chemistry at the Eidgennossische Technische Hochschule (ETH) in Zurich, Switzerland and did postdoctoral work at Harvard University.

Ms. Washington joined Gilead as Senior Vice President and Chief Financial Officer in May 2008. In this role, she oversees Gilead's worldwide Finance and Investor Relations functions. Prior to joining Gilead, Ms. Washington served as Chief Financial Officer of Hyperion Solutions, an enterprise software company that was acquired by Oracle Corporation in March 2007. Ms. Washington also spent nearly 10 years at PeopleSoft, a provider of enterprise application software, most recently in the role of Senior Vice President and Corporate Controller. She previously was a Director of Finance for Tandem Computers, an Accounting Analyst for the Federal Reserve Bank of Chicago and a Senior Auditor for Deloitte & Touche. Ms. Washington holds a bachelor's degree in business administration from the University of Michigan and a MBA from Pepperdine University. She currently serves on the Board of Directors of MIPS Technologies, Inc.

Gregg Alton joined Gilead Sciences in 1999. From 2000 to 2009 he served as General Counsel. In his current role, Mr. Alton is responsible for legal affairs, government affairs, medical affairs, public affairs and international access activities. Prior to joining Gilead, Mr. Alton was an attorney at the law firm of Cooley Godward, LLP, where he specialized in mergers and acquisitions, corporate partnerships and corporate finance transactions for healthcare and information technology companies. Mr. Alton is a member of the board and treasurer of the AIDS Healthcare Foundation, a member of the board of Oculus Innovative Sciences, Inc. and a member of the board of BayBio, a San Francisco Bay Area life sciences industry organization. Mr. Alton received a bachelor's degree in legal studies from the University of California at Berkeley, and holds a JD from Stanford University.

Dr. Cheng joined Gilead Sciences in 1999 and was appointed to his current role of Senior Vice President, Development Operations in February 2009. In this role, he is responsible for Gilead?s biometrics, clinical operations, drug safety and public health, project and portfolio management and regulatory affairs activities. Dr. Cheng previously served as Vice President, Clinical Research, overseeing Gilead?s clinical development activities for the company?s development-stage programs in HIV/AIDS. Prior to joining Gilead, Dr. Cheng trained in internal medicine at the University of California, Los Angeles. Dr. Cheng received his bachelor?s degree from the Johns Hopkins University and his medical degree and PhD in Cellular and Molecular Biology from Columbia University. He is board certified in internal medicine.

Mr. Caracciolo joined Gilead Sciences in 1997 and has served as Senior Vice President, Manufacturing since 2003 and Senior Vice President, Manufacturing and Operations since 2007. Prior to joining Gilead, Mr. Caracciolo spent six years as Vice President of Operations for Bausch & Lomb’s pharmaceutical division in Tampa, Florida and held various management positions at Sterling Drug, Inc. Mr. Caracciolo is a board member of the Keck Graduate Institute Advisory Council. Mr. Caracciolo received a bachelor’s degree in pharmaceutical science from St. John's University in New York State.

Paul Carter joined Gilead Sciences in 2006 and leads the company's commercial operations outside of North America. Prior to joining Gilead, Mr. Carter spent 14 years in various positions at GlaxoSmithKline (GSK), including as a General Manager in Europe and later as a Regional Head of international business in Asia. In this role he was a member of GSK's International Management Committee. Mr. Carter's experience also includes four years with Arthur Andersen's London practice. Mr. Carter is a fellow of the United Kingdom's Chartered Institute of Management Accountants. He holds a degree in Business Studies from Ealing School of Business and Management (now part of Thames Valley University).

Seigo Izumo, MD joined Gilead as Senior Vice President, Cardiovascular Therapeutics in September 2008. In this role, Dr. Izumo oversees Gilead?s growing cardiovascular business unit. Dr. Izumo most recently served as Vice President & Global Head of Cardiovascular Research at Novartis Institutes for BioMedical Research. Prior to joining Novartis in July 2003, he served as Professor of Medicine at Harvard Medical School in Boston and at Harvard-MIT Division of Health Sciences and Technology. In addition to his academic position at Harvard, Dr. Izumo was Director of Cardiovascular Research and Physician, Department of Medicine, Beth Israel Deaconess Medical Center, Boston and Director of the CardioGenomics Program, a National, Heart Lung and Blood Institute-sponsored initiative. Previously, he was Chief of the Cardiology Division and Professor of Internal Medicine and Biological Chemistry, University of Michigan Medical School in Ann Arbor. Dr. Izumo received his undergraduate and medical degrees from the University of Tokyo.

Manoj C. Desai, Ph.D. Manoj Desai has been Vice President, Medicinal Chemistry at Gilead Sciences since 2003. Previously he was Divisional Vice President of Research at Chiron from 1994 to 2003, where he was functional head of chemistry. His areas of leadership have included medicinal chemistry, chemical informatics, computational chemisty, protein X-ray crystallography, combinatorial chemistry, analytical chemistry and bioorganic chemistry. Prior to Chiron, he was a medicinal chemist for seven years at Pfizer Central Research. He received his Ph.D. from M.S. University of Baroda in Natural Products with Dr. Sukh Dev. Dr. Desai was a Post Doctoral Fellow in the laboratories of Professor Herbert C. Brown and Professor E.J. Corey. He is a section editor for Annual Report in Medicinal Chemistry and Current Opinion in Drug Discovery and Development.

Ms. Little is a managing director and business development manager at WRF Capital. She concentrates primarily in the areas of healthcare and biotechnology and is responsible for identifying and developing start-up opportunities and investment decisions in new companies. Ms. Little is WRF Capital's investment manager for Therus, EKOS, Trace Detect, Point of CareWare, Amnis, Pacific Bioscience Laboratories, Second Act Partners, Corus Pharma (acquired by Gilead Sciences) and serves on the board of directors of Accium Biosciences. Previously, Ms. Little was manager of technology licensing and acquisitions and senior technology licensing manager. Before joining WRF, she worked as a marketing manager and market consultant. Ms. Little has a bachelor of arts in zoology from Pomona College and a master's in business administration from the University of Arizona.

Francis V. Chisari, M.D. is currently Professor and Head of the Division of Experimental Pathology at the Scripps Research Institute. Dr. Chisari received his M.D. from Cornell University Medical College in 1968. He has been on the Scripps faculty since 1975 and has published over 325 papers in the area of hepatitis virus immunobiology and pathogenesis. Dr. Chisari sits on several advisory boards including the Distinguished Advisory Committee at the UCSD Cancer Center, the Scientific Advisory Board for the Center for the Study of HCV at Rockefeller University, the International Research Scholars Program at the Howard Hughes Medical Institute and various expert panels sponsored by the NIAID. In recognition of his scientific contributions, Dr. Chisari has received many honors and awards including election to fellowship in the American Association for the Advancement of Science and the American Academy of Microbiology, and membership in the Association of American Physicians, the National Academy of Sciences, and the Institute of Medicine.

Lynn Mazzaferro, Board Member, is a Therapeutic Specialist for Gilead Sciences. Lynn has been in the pharmaceutical industry for over 7 years. Prior to the pharmaceutical industry Lynn owned and operated a gymnastic school where her passion for teaching and business evolved. She is an active athlete who now participates in HIV/AIDS fundraisers to bring awareness to those infected and affected with HIV/AIDS.

Paul Klotman, MD is the Murray M. Rosenberg Professor of Medicine and the Chairman of the Samuel Bronfman Department of Medicine at the Mt. Sinai School of Medicine. Dr. Klotman?s research has been focused on the translation of molecular virology to AIDS pathogenesis. His laboratory developed the first small animal model of HIV associated nephropathy, demonstrating HIV causes HIVAN directly. More recent work has shown that HIV replicates in human renal epithelium, that the kidney is a reservoir for replicating virus and that the renal epithelium serves as a compartment distinct from peripheral blood. His laboratory has demonstrated the importance of the Nef gene in causing cellular proliferation through the Src pathway as a key component of renal pathogenesis. Dr. Klotman has been elected to both the American Society of Clinical Investigation and the Association of American Physicians. He has served on and chaired numerous study sections including those from the NIH, the American Heart Association, the National Kidney Foundation, and the Veterans Affairs research service.

Since 2000, Polly has worked in Rwanda in a number of capacities and sectors health, education, technology, community and rural development. She is currently at Gilead Sciences on the Public Affairs team, where she manages Gilead's corporate philanthropy and communications strategy for the company's access initiatives in the developing world. Separately, she is helping to support the development of the Maranyundo Initiative, with the twofold goal of increasing the number of girls in Rwanda who successfully enroll in and complete secondary school and pursue higher education, and training teachers nationally through the launch of a Virtual Teacher Training Institute. In addition, she is helping to raise support for Rwanda's national rural health scale-up plan and the first public library in Kigali. Prior to joining Gilead, Polly completed her MBA at the University of Michigan. There, she helped develop a capacity-building partnership between the University and Rwanda's Education, Finance and Public Service ministries and the School of Finance and Banking (SFB) in Kigali, as well as a joint project between the University and students at the Kigali Institute of Science and Technology (KIST). Prior to business school, Polly was the first Chief of Staff for the Clinton Foundation HIV/AIDS Initiative, and held positions in communications and development for other companies and nonprofit organizations.

Dr. Whitley joined Gilead’s Board of Directors in 2008. He also serves as the Loeb Scholar in Pediatrics; Director, Division of Pediatric Infectious Diseases; Vice-Chair, Department of Pediatrics; Senior Scientist, Department of Gene Therapy; Senior Scientist, Cancer Research and Training Center; Associate Director for Clinical Studies, Center for AIDS Research; and Co-Director, Center for Emerging Infections and Emergency Preparedness (CEIEP) for the institution. Dr. Whitley has held responsibility for the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group, is a past President of the International Society of Antiviral Research, chairs the Board of Scientific Councilors for the National Center for Infectious Diseases of the U.S. Centers for Disease Control and Prevention and is Vice President of the Board of the Infectious Disease Society of America.

Dr. Ernst received his Ph.D. in Microbiology and Molecular Genetics at the University of California, Los Angeles. Dr. Ernst has extensive experience in formulating and scaling-up commercial liposome products and in the design of molecular biology vectors for membrane bound proteins. He has seven years experience in the biotechnology and pharmaceutical industries and was employed for two years in the Product Development Department of Vestar, Inc. (now Gilead Sciences, Inc.).

Dr. Baker is currently at Gilead Sciences, following Gilead's acquisition of Corus in 2006. He joined Corus Pharma as Vice President, Research in June 2002, with more than 20 years of research and drug discovery experience. Prior to joining Corus Pharma, Dr. Baker was Chief Operating Officer and VP Research for Optimer Pharmaceuticals, Inc., where he focused on developing novel therapeutics for infectious disease and cancer. Previously, Dr. Baker served as Senior Vice President of Research and Preclinical Development for PathoGenesis Corporation. Prior to PathoGenesis, Dr. Baker was Associate Research Fellow at Abbott Laboratories, where he directed research in cardiovascular and anti-infective drug discovery. While at Abbott his research developed the 11, 12 carbamate reaction sequence and full sugar analogs technology that enabled the ketolide class of macrolide antibiotics. Dr. Baker received his Ph.D. in organic chemistry from the University of Illinois, Champaign and his BS degree in chemistry from the University of Washington.

Array

Mr. Denny joined Gilead's Board of Directors in 1996 and was appointed Lead Independent Director in May 2008. He served as Chairman from 2001 until May 2008. Previously, he was Chief Financial Officer and Vice Chair at Sears, Roebuck & Co. and held oversight responsibility for many of the company's operations and staff functions. Mr. Denny is currently a director of GATX Corporation and a member of the advisory boards for several privately-held fund management companies. He is a past Chairman of Northwestern Memorial Hospital and the Northwestern Memorial Foundation and has held directorships at Astra AB, ChoicePoint, Inc., The Principal Financial Group, The Allstate Corporation and General Instruments, Inc. Mr. Denny also served as Executive Vice President and Chief Financial and Planning Officer at G.D. Searle & Co., Chairman of Pearle Health Services, Inc. and Senior Advisor at William Blair Capital Partners, Treasurer at the Firestone Tire & Rubber Co. and associate counsel at Dewey, Ballantine, Bushby, Palmer and Wood in New York and Paris.

John W. Madigan is the retired chairman and CEO of Tribune Company. Tribune is a media industry leader with operations in 25 major markets throughout the United States. He was elected chief executive officer of Tribune in May 1995. He also served as chairman from 1996 through December 2003. He was elected to the Tribune board of directors in 1975, the same year he joined the company as vice president/chief financial officer. Madigan began his business career as a financial analyst with Duff & Phelps Inc. in Chicago and later became a manager at Arthur Andersen & Co. He was an investment banker with both Paine, Webber, Jackson & Curtis and Salomon Brothers. Madigan is a director of the Robert R. McCormick Foundation, Boise Cascade and Gilead Sciences; an advisor to Madison Dearborn Partners; and a past chairman of The Chicago Council on Global Affairs. He also serves as a trustee of Northwestern University, Rush University Medical Center and The Paley Center for Media in New York. A Chicago-area native, born June 7, 1937, Madigan holds bachelor's and master's degrees in business administration from the University of Michigan.

Dr. Berg joined Gilead's Board of Directors in 1998. He previously served as Professor and Chairman of the Department of Biochemistry and Director of the Beckman Center for Molecular and Genetic Medicine at the Stanford University School of Medicine. Dr. Berg is currently a director and scientific advisor to Affymetrix Inc. and a scientific advisor to Perlegen Sciences Inc. and Burrill and Co. He is a member of the U.S. National Academy of Sciences. In 1980, Dr. Berg was awarded the Nobel Prize for his fundamental studies of the biochemistry of nucleic acids. He was awarded the National Medal of Science in 1983.